NRG Pallas and Global Morpho Pharma are partnering to establish an independent radiopharmaceutical supply chain for non-carrier–added (n.c.a.) lutetium-177 (Lu-177) chloride in Petten, the Netherlands.
Under the agreement, Morpho's KaLupso automated radiochemistry platform will be deployed within NRG Pallas's nuclear infrastructure to produce GMP-grade n.c.a. Lu-177 chloride for Lu-177-based cancer therapies, according to the announcement. The location of NRG Pallas' reactor and processing facility on the same premises is designed to minimize isotope decay during transport and optimize yield, the companies said.
The partnership aims to supply n.c.a. Lu-177 to a broad range of customers -- from established radiopharmaceutical companies to startups and public institutions -- through a nonexclusive model, the firms said. Installation, qualification, and validation of KaLupso within the GMP isotope production facility is currently underway, with initial commercial delivery targeted for early 2027.
